Open-label placebo treatment in chronic low back pain: A randomized controlled trial

Detalhes bibliográficos
Autor(a) principal: Carvalho, Cláudia Maria Constante Ferreira de
Data de Publicação: 2016
Outros Autores: Joaquim António Machado Caetano, Cunha, Lidia, Rebouta, Paula, Kaptchuk, Ted J., Kirsch, Irving
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.12/5019
Resumo: This randomized controlled trial was performed to investigate whether placebo effects in chronic low back pain could be harnessed ethically by adding open-label placebo (OLP) treatment to treatment as usual (TAU) for 3 weeks. Pain severity was assessed on three 0- to 10-point Numeric Rating Scales, scoring maximum pain, minimum pain, and usual pain, and a composite, primary outcome, total pain score. Our other primary outcome was back-related dysfunction, assessed on the Roland-Morris Disability Questionnaire. In an exploratory follow-up, participants on TAU received placebo pills for 3 additional weeks. We randomized 97 adults reporting persistent low back pain for more than 3 months' duration and diagnosed by a board-certified pain specialist. Eighty-three adults completed the trial. Compared to TAU, OLP elicited greater pain reduction on each of the three 0- to 10-point Numeric Rating Scales and on the 0- to 10-point composite pain scale (P < 0.001), with moderate to large effect sizes. Pain reduction on the composite Numeric Rating Scales was 1.5 (95% confidence interval: 1.0-2.0) in the OLP group and 0.2 (-0.3 to 0.8) in the TAU group. Open-label placebo treatment also reduced disability compared to TAU (P < 0.001), with a large effect size. Improvement in disability scores was 2.9 (1.7-4.0) in the OLP group and 0.0 (-1.1 to 1.2) in the TAU group. After being switched to OLP, the TAU group showed significant reductions in both pain (1.5, 0.8-2.3) and disability (3.4, 2.2-4.5). Our findings suggest that OLP pills presented in a positive context may be helpful in chronic low back pain.
id RCAP_3c74c8909d47e91d6a2ee7bfc6345cdf
oai_identifier_str oai:repositorio.ispa.pt:10400.12/5019
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Open-label placebo treatment in chronic low back pain: A randomized controlled trialPlaceboChronic low back painControlled trialThis randomized controlled trial was performed to investigate whether placebo effects in chronic low back pain could be harnessed ethically by adding open-label placebo (OLP) treatment to treatment as usual (TAU) for 3 weeks. Pain severity was assessed on three 0- to 10-point Numeric Rating Scales, scoring maximum pain, minimum pain, and usual pain, and a composite, primary outcome, total pain score. Our other primary outcome was back-related dysfunction, assessed on the Roland-Morris Disability Questionnaire. In an exploratory follow-up, participants on TAU received placebo pills for 3 additional weeks. We randomized 97 adults reporting persistent low back pain for more than 3 months' duration and diagnosed by a board-certified pain specialist. Eighty-three adults completed the trial. Compared to TAU, OLP elicited greater pain reduction on each of the three 0- to 10-point Numeric Rating Scales and on the 0- to 10-point composite pain scale (P < 0.001), with moderate to large effect sizes. Pain reduction on the composite Numeric Rating Scales was 1.5 (95% confidence interval: 1.0-2.0) in the OLP group and 0.2 (-0.3 to 0.8) in the TAU group. Open-label placebo treatment also reduced disability compared to TAU (P < 0.001), with a large effect size. Improvement in disability scores was 2.9 (1.7-4.0) in the OLP group and 0.0 (-1.1 to 1.2) in the TAU group. After being switched to OLP, the TAU group showed significant reductions in both pain (1.5, 0.8-2.3) and disability (3.4, 2.2-4.5). Our findings suggest that OLP pills presented in a positive context may be helpful in chronic low back pain.Foundation for the Science of the Therapeutic Encounter (F-STE); National Center for Complementary and Integrative Health; U.S. National Institutes of HealthLippincott, Williams & WilkinsRepositório do ISPACarvalho, Cláudia Maria Constante Ferreira deJoaquim António Machado CaetanoCunha, LidiaRebouta, PaulaKaptchuk, Ted J.Kirsch, Irving2016-10-29T11:28:36Z2016-01-01T00:00:00Z2016-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.12/5019engPAIN, 0, 1-7. Doi: 10.1097/j.pain.000000000000070010.1097/j.pain.0000000000000700info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-05T16:40:45Zoai:repositorio.ispa.pt:10400.12/5019Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:22:51.257807Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Open-label placebo treatment in chronic low back pain: A randomized controlled trial
title Open-label placebo treatment in chronic low back pain: A randomized controlled trial
spellingShingle Open-label placebo treatment in chronic low back pain: A randomized controlled trial
Carvalho, Cláudia Maria Constante Ferreira de
Placebo
Chronic low back pain
Controlled trial
title_short Open-label placebo treatment in chronic low back pain: A randomized controlled trial
title_full Open-label placebo treatment in chronic low back pain: A randomized controlled trial
title_fullStr Open-label placebo treatment in chronic low back pain: A randomized controlled trial
title_full_unstemmed Open-label placebo treatment in chronic low back pain: A randomized controlled trial
title_sort Open-label placebo treatment in chronic low back pain: A randomized controlled trial
author Carvalho, Cláudia Maria Constante Ferreira de
author_facet Carvalho, Cláudia Maria Constante Ferreira de
Joaquim António Machado Caetano
Cunha, Lidia
Rebouta, Paula
Kaptchuk, Ted J.
Kirsch, Irving
author_role author
author2 Joaquim António Machado Caetano
Cunha, Lidia
Rebouta, Paula
Kaptchuk, Ted J.
Kirsch, Irving
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do ISPA
dc.contributor.author.fl_str_mv Carvalho, Cláudia Maria Constante Ferreira de
Joaquim António Machado Caetano
Cunha, Lidia
Rebouta, Paula
Kaptchuk, Ted J.
Kirsch, Irving
dc.subject.por.fl_str_mv Placebo
Chronic low back pain
Controlled trial
topic Placebo
Chronic low back pain
Controlled trial
description This randomized controlled trial was performed to investigate whether placebo effects in chronic low back pain could be harnessed ethically by adding open-label placebo (OLP) treatment to treatment as usual (TAU) for 3 weeks. Pain severity was assessed on three 0- to 10-point Numeric Rating Scales, scoring maximum pain, minimum pain, and usual pain, and a composite, primary outcome, total pain score. Our other primary outcome was back-related dysfunction, assessed on the Roland-Morris Disability Questionnaire. In an exploratory follow-up, participants on TAU received placebo pills for 3 additional weeks. We randomized 97 adults reporting persistent low back pain for more than 3 months' duration and diagnosed by a board-certified pain specialist. Eighty-three adults completed the trial. Compared to TAU, OLP elicited greater pain reduction on each of the three 0- to 10-point Numeric Rating Scales and on the 0- to 10-point composite pain scale (P < 0.001), with moderate to large effect sizes. Pain reduction on the composite Numeric Rating Scales was 1.5 (95% confidence interval: 1.0-2.0) in the OLP group and 0.2 (-0.3 to 0.8) in the TAU group. Open-label placebo treatment also reduced disability compared to TAU (P < 0.001), with a large effect size. Improvement in disability scores was 2.9 (1.7-4.0) in the OLP group and 0.0 (-1.1 to 1.2) in the TAU group. After being switched to OLP, the TAU group showed significant reductions in both pain (1.5, 0.8-2.3) and disability (3.4, 2.2-4.5). Our findings suggest that OLP pills presented in a positive context may be helpful in chronic low back pain.
publishDate 2016
dc.date.none.fl_str_mv 2016-10-29T11:28:36Z
2016-01-01T00:00:00Z
2016-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.12/5019
url http://hdl.handle.net/10400.12/5019
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv PAIN, 0, 1-7. Doi: 10.1097/j.pain.0000000000000700
10.1097/j.pain.0000000000000700
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Lippincott, Williams & Wilkins
publisher.none.fl_str_mv Lippincott, Williams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130089309339648